Project-specific
Process Capability
Analytical release is defined in the product specification and agreed scope.
Enterprise Scale-Up CDMO · Execution Intelligence
High-Volume Supplement Contract Manufacturing Without Batch Drift.
Analytical release is defined in the product specification and agreed scope.
Documented
Quality Complaints
Institutional QA record across enterprise programs
Project-defined
Batch Release Analytics
Every run released on analytical evidence, not assumptions
Agreed scope
Industrial Throughput
Gelatin and HPMC softgel formats
The Velvet Rope
Selective admission defines project scope.
We refuse mandates that are not ready for evidence-led execution. Selectivity safeguards the integrity of every active program and removes avoidable failure modes before they enter production.
- You are scaling a serious brand asset, not testing discount-market demand.
- You require defensible quality proof for boards, regulators, clinics, or investors.
- You expect documentation discipline that survives diligence and transfer.
- You are prepared to enter via Initiate R&D Due Diligence (paid).
Scale Protocol
Reproducibility Is the Product.
Capacity is easy to advertise. Controlled consistency at enterprise volume is hard to execute. Our scale-up method prioritizes process capability, analytical certainty, and transfer-grade documentation from day one.
Validation Standard
Analytical release is defined in the product specification and agreed scope.
Release Criteria
Release testing defined by product specification
Operational Continuity
Project-specific production scope
Governance
ISO 27001 + zero-conflict operating model
Diligence Outcomes
What Admission Actually Gives You.
A scale-up route engineered for compliance resilience, not quote velocity.
Operational documentation that survives board review and acquirer scrutiny.
An execution partner aligned to quality outcomes before production economics.
Execution Ladder
Four Moves from Pilot Promise to Enterprise Repeatability.
01
Admission Diligence
Technical triage determines scientific fit and scale-risk exposure before acceptance.
02
Process Architecture
We design quality-critical controls for reproducibility and compliance stability.
03
Analytical release is defined in the product specification and agreed scope.
Qualification runs prove capability before full commercial deployment.
04
Industrial Campaigns
Enterprise volume production under analytical release and transfer-ready documentation.
Final Gate
Initiate R&D Due Diligence.
If your mandate is to build a defensible, acquisition-grade supplement platform, we can evaluate fit. If your mandate is low-friction quote shopping, this gate is intentionally closed.
Analytical release is defined in the product specification and agreed scope.
Frequently Asked Questions
Why gate scale-up projects behind paid due diligence?
Because scale-up failure is expensive. We map formulation risk, process capability, and compliance pathways before acceptance. Paid due diligence filters out speculative briefs and protects execution quality for admitted partners.
What is validated during your scale-up admission process?
Analytical release is defined in the product specification and agreed scope.
Can enterprise QA teams audit your manufacturing and controls?
Qualified teams can review relevant quality documentation, batch records and testing requirements in Gdynia through the agreed written scope. Independent verification can be arranged where the project scope requires it.
What factors inform consistency planning for the agreed production scope?
Analytical release is defined in the product specification and agreed scope.
Who owns the formulation intelligence and process documentation?
The published starting MOQ is 5,000 units. Project scope, timing, batch requirements and release testing are confirmed in writing.
What happens if a project is not admitted after due diligence?
You receive a clear technical decision memo with the limiting factors and risk signals identified. We do not accept borderline projects that would compromise quality outcomes for either side.
RELATED INTELLIGENCE
Production Formats & MOQ ReferenceHard capsules 150K units, softgels 300K, sachets 75K — with finished-bottle counts at 30 and 60 per packEXPLORE ›Evidence-Based Supplement Formulation TechnologyLiposomal, enteric and micellar encapsulation for defensible bioavailability claimsEXPLORE ›Softgel Contract ManufacturingGelatin and HPMC softgel formats for food supplementsEXPLORE ›Physician-Formulated Supplement Brand CDMOClinical manufacturing for doctor-led brands with full IP transferEXPLORE ›IP & NDA Protection During Production Scale-UpISO 27001 secured technology transfer — your MBR stays yoursEXPLORE ›
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ is responsible for market-specific regulatory compliance, health claim authorisation, labelling and marketing of its finished product, as defined by the applicable agreement.